3081450-95-2
Chemical Structure
Yoda2
Synonym(s): KC289
- CAS No.: 3081450-95-2
- Formula:C16H9Cl2KN2O2S2
- Molecular Weight:435.39
IUPAC Name: potassium 4-(5-((2,6-dichlorobenzyl)thio)-1,3,4-thiadiazol-2-yl)benzoate
InChIKey: OQEIWUHZUPFUQU-UHFFFAOYSA-M
SMILES: O=C(O[K])C1=CC=C(C2=NN=C(SCC3=C(Cl)C=CC=C3Cl)S2)C=C1
Biological Activity: Yoda2 (KC289), the potassium salt of Yoda1 (HY-18723), is a PIEZO1 agonist with an EC50 of 150 nM. Yoda2 evokes Ca2+ elevation and NO-dependent relaxation. Yoda2 induces relaxation in mouse arterial and cavernous tissues. Yoda2 inhibits glucocorticoid-induced osteoclast formation and bone resorptive activity, reverses glucocorticoid-induced bone density loss and architectural deterioration, and does not induce medication-related osteonecrosis of the jaw in mice. Yoda2 can be used for the researches of hypertension and osteoporosis[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Yoda2 | 99.57% | Yoda2 (KC289), the potassium salt of Yoda1 (HY-18723), is a PIEZO1 agonist with an EC50 of 150 nM. Yoda2 evokes Ca2+ elevation and NO-dependent relaxation. Yoda2 induces relaxation in mouse arterial and cavernous tissues. Yoda2 inhibits glucocorticoid-induced osteoclast formation and bone resorptive activity, reverses glucocorticoid-induced bone density loss and architectural deterioration, and does not induce medication-related osteonecrosis of the jaw in mice. Yoda2 can be used for the researches of hypertension and osteoporosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. DosAnjos Moraes R, et al. Abstract P221: Yoda2, a Novel Piezo1 Agonist, Induces Relaxation in Mouse Vascular and Corpus Cavernosum Tissues[J]. Hypertension, 2024, 81(Suppl_1): AP221-AP221.
- [2]. Voudouris J D, et al. Elucidation of the effect of Piezo1 activation on Glucocorticoid-Induced Osteoporosis[J]. 2025.
- [3]. Parsonage G, et al. Improved PIEZO1 agonism through 4-benzoic acid modification of Yoda1. Br J Pharmacol. 2023;180(16):2039-2063. [Content Brief]
